Compare · ABT vs MAIA
ABT vs MAIA
Side-by-side comparison of Abbott Laboratories (ABT) and MAIA Biotechnology Inc. (MAIA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MAIA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 1918.4x MAIA ($82.7M).
- Over the past year, ABT is down 32.0% and MAIA is down 24.9% - MAIA leads by 7.1 points.
- MAIA has been more active in the news (13 items in the past 4 weeks vs 6 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 0 for MAIA).
- Company
- Abbott Laboratories
- MAIA Biotechnology Inc.
- Price
- $90.76-0.33%
- $1.34-1.10%
- Market cap
- $158.63B
- $82.7M
- 1M return
- +4.37%
- +2.28%
- 1Y return
- -31.95%
- -24.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2022
- News (4w)
- 6
- 13
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest MAIA
- MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
- MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
- MAIA Biotechnology Announces Open Market Purchases by CEO and Director
- Chief Executive Officer Vitoc Vlad bought $100,886 worth of shares (72,700 units at $1.39), increasing direct ownership by 8% to 976,121 units (SEC Form 4)
- Director Smith Stan bought $100,200 worth of shares (75,000 units at $1.34) (SEC Form 4)
- Chief Scientific Officer Gryaznov Sergei bought $2,690 worth of shares (2,000 units at $1.34), increasing direct ownership by 4% to 46,511 units (SEC Form 4)
- SEC Form 4 filed by Chief Executive Officer Vitoc Vlad
- SEC Form 4 filed by Chief Scientific Officer Gryaznov Sergei
- SEC Form 4 filed by Head of Finance Himmelreich Jeffrey C
- MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology